Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Medical and therapeutic skincare company Langer will expand into additional personal care categories with its acquisition of private label manufacturer Twincraft early next year, firm states in Nov. 14 release. Valued at $26.7 mil., the transaction is expected to close in the first quarter of 2007, Langer says. The acquisition of Twincraft, producer of specialty bar soap, will bring Langer into the health and beauty, amenities, mass and direct marketing channels, firm notes. The soap manufacturer grossed revenues of approximately $27.1 mil. for fiscal year 2005. For the nine months ended Sept. 30, the firm reported revenues of $20.7 mil. Twincraft President and CEO Peter Asch is expected to join Langer's board of directors. The firm employs approximately 200 people in its Winooski and Essex Junction, Vt., locations. The business is expected to remain in Vermont...

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts